普華和順(01358.HK)預計，集團於截至2023年12月31日止年度，應佔溢利介乎1.42億元至1.65億元人民幣，按年增加33%至55%。主要由於集團血液淨化業務及輸液器業務利潤貢獻的大幅增加。
《盈利預喜》普華和順(01358.HK)料年度溢利按年升最多55%
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.